Breast Cancer Coverage From Every Angle
Advertisement
Advertisement

Effect of Scalp-Cooling Device on Hair Loss in Women Receiving Chemotherapy for Breast Cancer

Use of a scalp-cooling device appears to reduce hair loss by about 50% in about 50% of patients with stage I or II breast cancer, when patients are treated with taxane- or anthracycline-based chemotherapy. Results of the SCALP trial were published in JAMA and showed that hair was successfully preserved in 48 of 95 women in the cooling group vs 0 of 47 women in the control group. The study was stopped early by the data and safety monitoring board when the P value crossed the interim analysis superiority boundary. Results appeared to be better in patients treated with taxane-based regimens: hair preservation rates were 16% with anthracycline-based treatment vs 59% with taxane-based treatment.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.